ClinicalTrials.gg
RecruitingNCT04145024Updated Dec 11, 2024

Giessen Pulmonary Hypertension Registry and Biobank

An observational study in Pulmonary Hypertension, sponsored by University of Giessen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-12-11.

Sponsored by University of Giessen · Observational

How we know

From the registry’s dates

  • Started Jul 1993; still recruiting 33 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hypertension, Pulmonary by University of Giessen — 5 open to participants now, 5 under way, none of them phase 3. Hypertension, Pulmonary · University of Giessen.

Planned enrollment
2nd of 11
10,000 · median 500
Started
1993
the only one that year
Observational
11 of 13
5 open now
Registered
7th of 13
by date

Among the 13 studies in Hypertension, Pulmonary by University of Giessen, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 1993, is one of 11 observational ones, and was the 7th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

5 of the 13 studies in Hypertension, Pulmonary by University of Giessen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hypertension, Pulmonary by University of Giessen, or all of them as a file.
02

Study summary

Giessen Pulmonary Hypertension Registry and Biobank

Read the detailed description

Long-term transplant-free survival and its determinants will be investigated in patients with Pulmonary Hypertension (diagnosed by right heart catheterization) within a prospective registry at a single referral center in Giessen, Germany.

03

Conditions studied

  • Pulmonary Hypertension
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population includes patients referred to our tertial PH expert center in Giessen with suspected PH.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Right heart catheterization for PH diagnosis in Giessen

Exclusion criteria

Exclusion Criteria:

  • missing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
20 Years
Patient registry
Yes

Groups and cohorts

  • Pulmonary arterial hypertension

    Group 1 PH

  • Pulmonary hypertension due to left heart disease

    Group 2 PH

  • Pulmonary hypertension due to lung disease

    Group 3 PH

  • Chronic thromboembolic pulmonary hypertension

    Group 4 PH

  • Miscellaneous

    Group 5 PH

  • Exclusion PH

    Patient with invasively excluded PH

06

What researchers measure

Primary outcomes

  1. Survival

    Transplant-free survival of PH patients

    Time frame: Up to 20 years after enrollment

07

Study locations

1 of 1 sites recruiting
  • Department of Intermal Medicine - Universities of Giessen and Marburg Lung Center
    Giessen, 35392, Germany
    Recruiting
08

References and documents

Publications

  • Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, Franco OH, Hofman A, Schermuly RT, Weissmann N, Grimminger F, Seeger W, Ghofrani HA. The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. J Heart Lung Transplant. 2017 Sep;36(9):957-967. doi: 10.1016/j.healun.2017.02.016. Epub 2017 Feb 17. PubMed 28302503 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 1993 (actual). Primary completion is estimated for Jul 2035, 504 months after the start.

Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 504 months is above that.

Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2019
First posted
Oct 30, 2019
StartActual
Jul 1993
Primary completionEst.
Jul 15, 2035
CompletionEst.
Jan 15, 2036
Last update
Dec 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04145024
Lead sponsor
University of Giessen
Responsible party
Sponsor
First posted
Oct 30, 2019
Start date
Jul 1993
Primary completion
Jul 15, 2035 (estimated)
Completion
Jan 15, 2036 (estimated)
Last update
Dec 11, 2024

Study contacts

Khodr Tello, MD
Contact
khodr.tello@innere.med.uni-giessen.de
0641/985-51250 ext. 57030
Khodr Tello, MD
principal investigator · University Clinics of Giessen and Marburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion